Buy this stock that offers discounted exposure to SpaceX, Morgan Stanley says

On September 14, 2026, Dyne Therapeutics (DYN) presented its business plans at the Morgan Stanley Global Healthcare Conference, highlighting two significant milestones: a pending Duchenne muscular dystrophy (DMD) approval and a planned launch of DM1 the following year. Company officials conveyed a confident outlook while acknowledging the usual challenges related to regulation, payer coverage, and manufacturing scale-up.

Dyne Therapeutics announced it was entering a crucial commercial phase, with a January 2024 Priority Review Voucher Application (PDUFA) date for DYNE-101 in DMD and the DM1 launch scheduled for the subsequent year. The firm disclosed a cash position of $1.3 billion, which should enable multiple launches and a cost-effective expansion strategy.

The company's FORCE platform, which employs a transferrin receptor 1-targeting Fab and antisense oligonucleotide payload to reach muscle and, in certain instances, the central nervous system, was emphasized by management as a key differentiator. Dyne Therapeutics cited functional data in DMD and DM1 as proof of its differentiation from competitors, including Novartis.

The firm aims to broaden its product portfolio beyond exon 51 in DMD and employ a basket-trial approach to create a wider market. Dyne Therapeutics' leadership, including President and Chief Executive Officer John Cox and Chief Financial Officer Erick Lucera, emphasized the company's integration and readiness for commercialization. Both highlighted that the team has been assembled and equipped over the past two years to support the imminent launch.

Dyne Therapeutics did not provide details on quarterly revenue but underscored the importance of its balance sheet and capital structure. The company recently completed a successful capital raise, with a cash position of $1.3 billion at the end of the last quarter. Management stated that this capital position would support more than one product launch simultaneously.

The DMD program is on track for a January 2024 PDUFA decision, with priority review and no anticipated advisory committee meeting based on the FDA filing acceptance letter. Functional improvements were observed across all six key measures in DMD, with rise from floor velocity improving within six months and dystrophin expression reaching approximately 5.5% of normal at six months.

Dystrophin levels tripled from that point in longer-term voluntary biopsies, and functional improvements persisted through 18 to 24 months post-treatment. Cardiac and lung function appeared to stabilize in both ambulatory and non-ambulatory boys. Dyne Therapeutics reported that its dystrophin production is about 10 times higher than that of EXONDYS 51, a competitor drug.

The DM1 program is progressing towards a planned launch the following year, with both accelerated and confirmatory development pathways in place. The ACHIEVE study demonstrated DMPK knockdown and splicing correction, indicating core pathobiology targeting. Functional gains were observed in five-times sit-to-stand, hand myotonia measured by VHOT, and patient-reported outcomes on the MDHI across six subscales.

The registrational expansion cohort comprises 71 patients, with the Phase III HARMONIA trial now enrolling, using five-times sit-to-stand as the primary endpoint. Long-term extension data will be presented at AANEM and World Muscle conferences, including 12-month data from the registrational expansion cohort. Dyne Therapeutics estimated the DM1 patient population at more than 30,000 individuals and noted that the disease shortens life by about two decades.